While on average, rises in absolute counts were most obvious during the first 3 months, rises in percentages were Venetoclax solubility dmso more progressive over the whole observation period
although in neither case did they reach median values seen in HIV-uninfected controls ( Fig. 1A and D). In contrast, no statistically significant trends in absolute CD8+ T cell and CD19+ B cell counts were seen over the same period ( Fig. 1B and C). Values for CD8+ T cells remained above those seen in uninfected controls showing some apparent trend towards these normal values ( Fig. 1B and E) but median CD19+ B cell values remained consistently lower than control values ( Fig. 1C and F). Extending our recent report of an apoptosis-prone phenotype in HIV-infected children,10 we measured trends in circulating B cell subsets during 12 months’ ART and observed increases in proportions of both mature naïve (CD19+ CD10− CD27− CD21hi) and resting memory B cells (CD19+ CD27+ CD21hi) (P < 0.0001, P = 0.04) which occurred largely over the first 3 months and to
levels, in the former subset, that were higher than those seen in uninfected controls while in the latter they remained HSP inhibition below normal median values ( Fig. 2A–B). There were corresponding falls in proportions of apoptosis-prone mature activated (CD19+ CD21lo CD10−) B cells (P < 0.0001) to levels seen in uninfected controls ( Fig. 2C). However, no significant or consistent trends in numbers of apoptosis-prone immature transitional (CD19+ CD10+ CD27−) B cell
percentages were observed ( Fig. 2D). In contrast to total B cell subsets, recovery in ADP ribosylation factor numbers of circulating memory B cells specific for four pneumococcal antigens (Choline binding protein A (CbpA), Pneumococcal surface protein A (PspA), Pneumolysin (Ply) and Pneumococcal surface antigen A (PsaA)) only became apparent during the latter part of the 12 month observation period (P = 0.007, P = 0.02, P = 0.02, P = 0.001 respectively ( Fig. 3)). Median values approached those seen in uninfected controls by 12 months for two of the three antigens for which control data were available ( Fig. 3). The reversal of the immunodeficiency, in particular T cell function, associated with untreated HIV and following the initiation of ART is well described.5, 18, 23, 34, 35 and 36 The impact of ART on recovery of B cell function has received less attention. Here we describe reconstitution of B lymphocyte subsets in juxtaposition with reappearance of pneumococcus-specific memory B cells in Malawian children. Alongside normalization of CD4 and CD8 subsets, correction of B cell subset counts, including mature naïve, resting memory and apoptosis-prone mature activated B cells had largely occurred by 3 months after commencement of ART.